Breast Care最新文献

{"title":"New Perspectives in the Management of Triple-Negative Breast Cancer.","authors":"Rupert Bartsch, Zsuzsanna Bago-Horvath, Daniel Egle, Simon P Gampenrieder, Birgit Grünberger, Sonja Heibl, Maximilian Marhold, Caroline Preuss, Gabriel Rinnerthaler, Kathrin Strasser-Weippl, Christoph Suppan, Christian F Singer, Michael Gnant","doi":"10.1159/000547988","DOIUrl":"10.1159/000547988","url":null,"abstract":"<p><strong>Background: </strong>The biological heterogeneity of triple-negative breast cancer (TNBC) and the availability of a growing number of therapeutic options necessitate continuous redefinition of the ideal treatment algorithm for patients with TNBC. Austrian experts convened for an advisory board meeting in November 2024 to discuss standards of care in the early and metastatic settings with a focus on the healthcare situation in Austria.</p><p><strong>Summary: </strong>This paper discusses biological principles, (neo)adjuvant treatment standards and strategies of escalation and de-escalation, as well as standards of care, new treatment options, and the management of central nervous system (CNS) disease in the setting of metastatic TNBC.</p><p><strong>Key messages: </strong>TNBC remains a high-risk subtype of breast cancer. Neoadjuvant chemotherapy is preferred in early-stage disease starting from cT1c, cN0, with the addition of pembrolizumab recommended from clinical stage II. Post-neoadjuvant treatment is guided by the pathological response and <i>BRCA</i> mutation status, while ongoing trials are evaluating the role of antibody-drug conjugates in this setting. In metastatic TNBC, assessment of PD-L1 expression and <i>BRCA</i> mutation status is essential for optimal sequencing of available treatment options. CNS involvement remains a major clinical challenge.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"152-165"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503879/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Should Sonographic Abnormal Axillary Lymph Nodes Be Excised in Sentinel Node Biopsy of Breast Cancer?","authors":"Xing Wang, Zhaoqing Fan, Ling Huo, Tie Fan, Xinguang Wang, Wei Cao, Yingjian He, Tao Ouyang","doi":"10.1159/000548074","DOIUrl":"10.1159/000548074","url":null,"abstract":"<p><strong>Background: </strong>In sentinel node biopsy (SNB) procedure for breast cancer patient, whether the abnormal node was excised is uncertain. The impact of abnormal node on the accuracy of SNB results is unknown.</p><p><strong>Methods: </strong>In this prospective study, breast cancer patients with sonographically abnormal axillary lymph nodes (SAALNs) and negative FNAC results were eligible. Before the SNB operation, a localization wire was placed at the SAALN by ultrasound guidance. In the SNB operation, the wire-localized nodes (WLNs) and radioactive nodes were excised and labeled separately for pathological examination.</p><p><strong>Results: </strong>In total, 213 WLNs, 169 (79.3%) were sentinel nodes (SNs) and 44 (20.7%) were non-SNs. 79 (37.1%) patients had positive SNs and 63 (29.6%) patients had positive WLNs both identified by pathological examination. 80 (37.6%) patients had positive lymph nodes whether it was SNs or WLNs. Omission diagnosis rate of SNB was 1.3% (1/80). Three axillary recurrence events (3/133, 2.3%) occurred in SN and WLN both negative patients at a median follow-up time of 132 months.</p><p><strong>Conclusions: </strong>Performing SNB by excising the SAALNs with negative FNAC simultaneously in breast cancer patients could reduce the omission diagnosis rate marginally, and the risk of axillary local recurrence is low.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"109-116"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503881/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Statement: Paper by Sabin Goktas Aydin, Ahmet Bilici, Omer Fatih Olmez, Basak B. Oven, Ozgur Acikgoz, Tansel Cakir, Pelin Basim, Asli Cakir, Yasin Kutlu, and Jamshid Hamdard entitled \"The Role of 18F-FDG PET/CT in Predicting the Neoadjuvant Treatment Response in Patients with Locally Advanced Breast Cancer\" [Breast Care. 2022;17(5):470-479. https://doi.org/10.1159/000524446].","authors":"","doi":"10.1159/000550972","DOIUrl":"10.1159/000550972","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.1159/000524446.].</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"166"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12999211/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147484645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"10.1159/000547496","DOIUrl":"10.1159/000547496","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1159/000546080.].</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"167-168"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced Glycation End Products: A Promising Prognostic Indicator in Breast Cancer Patients.","authors":"Gülcin Sahingoz Erdal, Nilgun Isiksacan, Murat Cikot, Mustafa Yaman, Esra Yildirim Servi, Elif Ede Cintosun, Sevgi Kalkanli Tas, Tamay Seda Tasci, Nursel Kocamaz, Dilay Karabulut","doi":"10.1159/000547938","DOIUrl":"10.1159/000547938","url":null,"abstract":"<p><strong>Introduction: </strong>Advanced glycation end products (AGEs) form through long-term reactions between proteins/lipids and sugars, accumulating in tissues and contributing to disease. AGEs are linked to cancer progression, with studies showing associations with colon and pancreatic cancer.</p><p><strong>Methods: </strong>This study investigates the relationship between AGEs and breast cancer. Stage 2-3 breast cancer patients and age-matched healthy controls were included. Exclusion criteria were diabetes, renal/liver disease, chronic inflammation, and infection. Blood samples were collected from patients pre-surgery and 48 h post-surgery and once from fasting controls. Glyoxal (GO) and methylglyoxal (MGO) levels were measured via liquid chromatography. A total of 60 breast cancer patients and 21 controls participated.</p><p><strong>Results: </strong>GO and MGO levels were significantly higher in patients than controls (<i>p</i> < 0.001) and decreased post-surgery. No significant differences were found between breast cancer subtypes. AGE levels did not correlate with age, lymph node involvement, or menopause status.</p><p><strong>Conclusion: </strong>The significant drop in AGE levels post-surgery suggests tumor burden influences AGE levels. While their predictive value remains uncertain, AGEs could serve as prognostic biomarkers. Monitoring AGEs may encourage lifestyle changes, and rising levels might indicate cancer recurrence or progression.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":"102-108"},"PeriodicalIF":2.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503891/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2026.","authors":"Marc Thill, Volkmar Müller, Tanja Fehm, Ute-Susann Albert, Maggie Banys-Paluchowski, Rupert Bartsch, Ingo Bauerfeind, Vesna Bjelic-Radisic, Jens Blohmer, Peter Dall, Eva Maria Fallenberg, Peter A Fasching, Michael Friedrich, Oleg Gluz, Nadia Harbeck, Andreas Hartkopf, Jörg Heil, Juliane Hörner-Rieber, Jens Huober, Wolfgang Janni, Hans-Heinrich Kreipe, David Krug, Thorsten Kühn, Sherko Kümmel, Sibylle Loibl, Diana Lüftner, Michael Patrick Lux, Nicolai Maass, Christoph Mundhenke, Mattea Reinisch, Toralf Reimer, Kerstin Rhiem, Achim Rody, Marcus Schmidt, Andreas Schneeweiss, Florian Schütz, Hans-Peter Sinn, Christine Solbach, Erich-Franz Solomayer, Elmar Stickeler, Michael Untch, Marion van Mackelenbergh, Isabell Witzel, Achim Wöckel, Rachel Würstlein, Nina Ditsch, Tjoung-Won Park-Simon","doi":"10.1159/000551511","DOIUrl":"https://doi.org/10.1159/000551511","url":null,"abstract":"<p><p>The Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO) presents the 2026 update of the evidence-based recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13229508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148155411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Liposuction and Glandular Excision for Gynecomastia: Clinical Presentation, Immediate Outcome, and Patient Satisfaction: A Cohort Study.","authors":"Mohammed Nasser Asiri, Mohammed Yousof Bakhiet, Meysaa Abdalazim Abdalrahim Ahmed, Alshareef Mohammed Alshareef, Aimen Elsheikh Khalil Abuelnour, Rayan A Alzahrani, Saja M Alghamdi","doi":"10.1159/000551464","DOIUrl":"https://doi.org/10.1159/000551464","url":null,"abstract":"<p><strong>Background: </strong>Gynecomastia can cause significant psychological distress, affecting the patient's self-esteem and quality of life, particularly in young adults. The treatment of gynecomastia encompasses simple observation and various surgical options. The surgical modalities of gynecomastia range from liposuction alone to subcutaneous gland excision and skin reduction. The study aimed to evaluate clinical presentation, surgical intervention modality, aesthetic outcomes, and patient satisfaction following gynecomastia surgery.</p><p><strong>Methods: </strong>This retrospective, cohort, hospital-based study included patients with gynecomastia who met our inclusion criteria from June 2023 to December 2024. Patients with incomplete records, with abnormal hormonal assays, diagnosed with fatty breast, or who needed skin excision were excluded from the study.</p><p><strong>Results: </strong>Seventy-one patients who underwent breast liposuction with glandular excision were included in the study. The mean age of the participants was 24 ± 3.9 years, and the mean BMI was 26.3 ± 2.6. Most participants (<i>n</i> = 55, 77.5%) were diagnosed with gynecomastia grade II. The average operation time was 45.6 ± 4.7 min, with a range of 32-58 min. All procedures were completed without complications. Postoperative complications were reported in 12.7% of the participants, including superficial skin necrosis, seroma, ecchymosis, and hematoma. Most of the participants (87.3%) rated their satisfaction as very good. A significant association was noticed between high BMI and postoperative complications (<i>p</i> = 0.030), as well as a low level of satisfaction (<i>p</i> = 0.029).</p><p><strong>Conclusions: </strong>Breast liposuction and glandular excision are effective and safe surgical procedures for gynecomastia surgery. The result yields high patient satisfaction and a low complication rate. BMI is considered a crucial factor that influences surgical outcomes.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13175577/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147962324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2026.","authors":"Tjoung-Won Park-Simon, Volkmar Müller, Ute-Susann Albert, Maggie Banys-Paluchowski, Rupert Bartsch, Ingo Bauerfeind, Vesna Bjelic-Radisic, Jens-Uwe Blohmer, Peter Dall, Nina Ditsch, Eva M Fallenberg, Peter A Fasching, Tanja Fehm, Michael Friedrich, Oleg Gluz, Nadia Harbeck, Andreas Daniel Hartkopf, Jörg Heil, Juliane Hörner-Rieber, Jens Huober, Hans-Heinrich Kreipe, David Krug, Thorsten Kühn, Sherko Kümmel, Sibylle Loibl, Diana Lüftner, Michael Patrick Lux, Nicolai Maass, Christoph Mundhenke, Toralf Reimer, Mattea Reinisch, Kerstin Rhiem, Achim Rody, Marcus Schmidt, Andreas Schneeweiss, Florian Schütz, Hans-Peter Sinn, Christine Solbach, Erich-Franz Solomayer, Elmar Stickeler, Michael Untch, Marion Tina van Mackelenbergh, Isabell Witzel, Achim Wöckel, Rachel Wuerstlein, Wolfgang Janni, Marc Thill","doi":"10.1159/000551512","DOIUrl":"10.1159/000551512","url":null,"abstract":"","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13225848/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148148251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refining Risk Assessment for Adjuvant CDK4/6 Inhibitors beyond Trial Inclusion Criteria: Integrating Recurrence Score and Endocrine Responsiveness according to ADAPT.","authors":"Michael Braun, Oleg Gluz, Sherko Kuemmel, Ulrike Nitz, Kerstin Luedtke-Heckenkamp, Maren Darsow, Helmut Forstbauer, Silke Polata, Eva-Maria Grischke, Christoph Uleer, Bahriye Aktas, Claudia Schumacher, Christine Zu Eulenburg, Ronald Kates, Sandy Burmeister, Monika Graeser, Rachel Wuerstlein, Rick Baehner, Matthias Christgen, Hans Heinrich Kreipe, Nadia Harbeck","doi":"10.1159/000550825","DOIUrl":"10.1159/000550825","url":null,"abstract":"<p><strong>Introduction: </strong>In HR+/HER2- high-risk early breast cancer (eBC), the NATALEE and monarchE trials demonstrated improved survival after the addition of CDK4/6 inhibitors to endocrine treatment (ET). However, the absolute benefit varies according to prognostic factors. We analyzed the outcome of subgroups based on monarchE and NATALEE inclusion criteria in the WSG-ADAPT-HR+/HER2- trial investigating Ki67 response to ET in treatment decision.</p><p><strong>Methods: </strong>In WSG-ADAPT-HR+/HER2- (NCT01779206), HR+/HER2- eBC patients with cT2-4 or cN+ or G3 or baseline Ki67 ≥15% received 3-week induction ET. pN0-1 patients with RS 0-11 or RS 12-25 with ET-response (central Ki67_postET ≤10%) received ET alone (ET subtrial); patients with RS 12-25 and no ET-response received chemotherapy (CTx) in CTx subtrial. Patients with c/pN2-3 or G3 with Ki67 >40% were randomized directly to CTx subtrial evaluating (neo)adjuvant paclitaxel vs. nab-paclitaxel, followed by epirubicin + cyclophosphamide and ET. For this retrospective analysis, the intermediate-risk group (meeting NATALEE but not monarchE criteria for \"high risk\") included patients with N0 and T3-4 or T2 with G3, or RS >25 or baseline Ki67 ≥20%, and those with N1, T1-2, G1-2, and RS ≤25. The high-risk group (meeting monarchE criteria for \"high risk\") included remaining patients with node-positive eBC, and the low-risk group included remaining N0 patients.</p><p><strong>Results: </strong>In the CTx (<i>n</i> = 2,230) and ET subtrials (<i>n</i> = 2,135), 609 and 481 patients were at intermediate risk, and 963 and 303 were at high risk, respectively. Risk classifications were prognostic in ET and CTx subtrials (median follow-up: 60 months). Low-risk patients in the ET subtrial (<i>n</i> = 1,351) had 5-year invasive disease-free survival (iDFS) and distant DFS (dDFS) of 94.7% and 96.4%, respectively, vs. 90.1% and 93.6% for intermediate-risk patients, and vs. 88.3% and 88.9% for high-risk patients. In the CTx-subtrial, 5-year iDFS and dDFS rates were 93.9% and 94.9% in the low-risk group (<i>n</i> = 658), versus 84.7% and 87.0% in the intermediate-risk group, and 77.7% and 79.6% in the high-risk group. Survival outcomes were similar between pN0 and pN1 intermediate-risk patients in the ET and CTx subtrials.</p><p><strong>Conclusion: </strong>Among 4365 WSG-ADAPT-HR+/HER2- patients, N0-1 cases receiving ET after ET-response and meeting NATALEE but not monarchE criteria had only slightly inferior outcomes vs. the low-risk group. Assuming a hazard ratio of 0.7 for a ribociclib effect in NATALEE, an absolute benefit of approximately 2% fewer dDFS events after 5 years could be expected in this group based on the WSG-ADAPT-HR+/HER2- experience. ET-response evaluation can refine prognosis to better inform shared decision-making in this intermediate-risk group.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12981907/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147467043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patients Diagnosed with Sclerosing Adenosis in Core Needle Biopsies: When Should Excision Be Performed?","authors":"Kayra Cangoz, Ebru Menekse, Muhammed Bahadir Avci, Birol Korukluoglu","doi":"10.1159/000550847","DOIUrl":"10.1159/000550847","url":null,"abstract":"<p><strong>Introduction: </strong>Although sclerosing adenosis (SA) carries a minimal risk of invasive breast cancer, atypical lesions, ductal carcinoma in situ, and invasive carcinoma may coexist with it. The literature does not offer a clear consensus on whether such cases warrant routine excision or can be managed through surveillance. This research aimed to evaluate the efficacy of core needle biopsy (CNB) in detecting coexisting atypical or malignant lesions (A/ML) in patients diagnosed with SA, by comparing CNB results with those of secondary excisional biopsy. Additionally, it seeks to identify the preoperative factors associated with lesion coexistence, to help determine which cases require excision.</p><p><strong>Patients and methods: </strong>A retrospective analysis was conducted on 165 patients diagnosed with SA by CNB and subsequently underwent an excisional biopsy between May 2019 and September 2023 at Ankara Bilkent City Hospital, Turkey. The sensitivity and specificity of CNB in detecting A/ML coexisting with SA were evaluated. Preoperative risk factors and radiological characteristics were analyzed in a subgroup of patients with SA who showed no evidence of A/ML on CNB but subsequently underwent secondary excisional biopsy. This subgroup was dichotomized as benign or A/ML based on final pathology. Univariate and multivariate analyses were then performed to identify preoperative factors associated with lesion coexistence.</p><p><strong>Results: </strong>The sensitivity and specificity of CNB in detecting A/ML coexisting with SA were 55% and 89%, respectively. In the main subgroup, age at SA diagnosis based on CNB (ROC curve cutoff: 37.5 years), lesion size (ROC curve cutoff: 1.45 cm), and preoperative magnetic resonance imaging requirement were identified as significant predictors of coexisting A/ML in multivariate analysis. The likelihood of coexisting A/ML increased to 20.8% when two predictors were present and to 50.0% when all three were combined.</p><p><strong>Conclusion: </strong>Given the limited sensitivity of CNB in detecting A/ML coexisting with SA, excisional biopsy may be warranted for selected patients - particularly those with two or more preoperative risk factors.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13012786/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147509703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}